AlloPrime

AlloPrime is an investigational immunomodulatory vaccine developed by Mirror Biologics. It is designed to create immunity against alloantigens, resulting in high titers of anti-allogeneic memory T-cells of the Th1 phenotype. These allo-specific memory Th1 cells can be non-specifically activated by inflammatory cytokines released during viral infections, leading to a feed-forward enhancement of interferon-gamma production and activation of innate immune cells such as Natural Killer (NK) cells. This mechanism aims to provide broad heterologous immunity against viral infections, particularly in older adults. A Phase I/II clinical trial has been cleared by the US FDA for evaluation in healthy adults over 65 years old[9][6].

Brand names

AlloPrime

Other names

AlloPrime